4,875 Shares in Solventum Co. (NYSE:SOLV) Acquired by Madison Investment Advisors LLC

Madison Investment Advisors LLC acquired a new position in shares of Solventum Co. (NYSE:SOLV - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 4,875 shares of the company's stock, valued at approximately $322,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Modus Advisors LLC purchased a new position in shares of Solventum during the fourth quarter worth approximately $25,000. Stonebridge Financial Group LLC purchased a new position in Solventum in the 4th quarter worth $26,000. Crews Bank & Trust purchased a new position in Solventum in the 4th quarter worth $32,000. True Wealth Design LLC lifted its stake in Solventum by 23,550.0% in the third quarter. True Wealth Design LLC now owns 473 shares of the company's stock worth $33,000 after purchasing an additional 471 shares during the last quarter. Finally, Prospera Private Wealth LLC purchased a new stake in Solventum during the third quarter valued at about $35,000.

Solventum Stock Down 0.9 %

Shares of NYSE SOLV traded down $0.68 during mid-day trading on Wednesday, hitting $74.25. 1,900,369 shares of the stock traded hands, compared to its average volume of 1,428,247. The stock has a fifty day moving average price of $75.38 and a 200-day moving average price of $71.73. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The company has a market cap of $12.84 billion and a price-to-earnings ratio of 27.00. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $85.92.

Remove Ads

Wall Street Analyst Weigh In

SOLV has been the subject of a number of recent research reports. Mizuho boosted their target price on Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a research note on Monday, March 3rd. Wells Fargo & Company raised their target price on shares of Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a report on Friday, February 28th. Morgan Stanley upped their price target on shares of Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a report on Wednesday, March 5th. The Goldman Sachs Group raised their price target on shares of Solventum from $63.00 to $71.00 and gave the stock a "sell" rating in a report on Monday, March 3rd. Finally, Bank of America raised their target price on Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $79.86.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.